SCHEMBL3769348

SCHEMBL3769348

O=C(CN1CCCCCC1)N1CCN(C2CCCC2)CC1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.69
ALDH1A1 P00352 5/20 0.58
KDM4E B2RXH2 3/20 0.58
SIGMAR1 Q99720 1/20 0.54
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.50
HSD17B10 Q99714 1/20 0.50
PHGDH O43175 1/20 0.50
MGLL Q99685 1/20 0.50
HRH3 Q9Y5N1 3/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
L3MBTL3 Q96JM7 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092628 1.00 GAA (0.69) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL13005710 0.93 KDM4E (0.68) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL13005059 0.93 KDM4E (0.68) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL3769500 0.93 KDM4E (0.68) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL3774221 0.93 KDM4E (0.68) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL3774024 0.93 KDM4E (0.68) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL3767809 0.93 SIGMAR1 (0.57) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL13005070 0.92 KDM4E (0.65) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL3773620 0.90 KDM4E (0.68) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL3780589 0.90 KDM4E (0.63) GAAALDH1A1KDM4ESIGMAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 GAA 2143/4885ALDH1A1 1210/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.